Doxorubicin Hydrochloride Liposomal

盐酸多柔比星脂质体

Report date: 2026/05/26 20:00:28

Base Information

Drug NameDoxorubicin Hydrochloride Liposomal
Drug Alias NameDoxorubicine Hydrochloride Liposomal盐酸阿霉素脂质体Chloridrato de Doxorrubicina Liposomal亚德里亚霉素脂质体Doxorubicina Hydrochloride Liposomal +[14] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibiotics
Mechanisms of ActionDNA intercalatorsTopoisomerase II inhibitors
TargetsTopoisomerase IIDNA
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaSolid tumoursPsychological Distress +[62] 
Global Approved IndicationsOvarian NeoplasmsBreast NeoplasmsMultiple Myeloma +[5] 
Approved Indications in ChinaNeoplasmsSarcoma, Kaposi
Original Approved Country/TerritoryUnited States
Original Approved Date1995/11/17
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBaxter Healthcare Corp
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineHefei University Of TechnologyWuhu Changjiang Pharmaceutical Co Ltd +[14] 
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Sun Pharma Advanced Research Company LtdJohannes Gutenberg-University Mainz +[50] 
Active IndicationsPrimary mediastinal B cell lymphomaLymphoproliferative DisordersNeoplasm Metastasis +[17] 
Inactive IndicationsSolid tumoursPsychological DistressHand-Foot Syndrome +[45] 

Other Information

ATC CodeL01DB01
Related LinksWikipediaDrugBankKEGG